Milestone Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Milestone Pharmaceuticals Inc. (MIST) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-20
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-09-30 was 4.09%, a 39.12% increase year-over-year.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-06-30 was 3.77%, a 38.60% increase year-over-year.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.95%, a 74.78% increase year-over-year.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-09-30 was 2.94%, a 212.77% increase year-over-year.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.30%, a 3.12% increase from fiscal 2024.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.17%, a 5.04% increase from fiscal 2023.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.97%, a 63.37% increase from fiscal 2022.
- Milestone Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.43%, a 131.43% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.30% 10-K · filed 2026-03-20 | |||
| 2024-12-31 | 4.17% 10-K · filed 2026-03-20 | |||
| 2023-12-31 | 3.97% 10-K · filed 2025-03-13 | |||
| 2023-09-30 | 4.09% 10-Q · filed 2023-11-13 | 3.92% 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | 3.77% 10-Q · filed 2023-08-10 | 3.91% 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | 3.95% 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | 2.43% 10-K · filed 2024-03-21 | |||
| 2022-09-30 | 2.94% 10-Q · filed 2023-11-13 | 2.41% 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | 2.72% 10-Q · filed 2023-08-10 | 2.31% 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | 2.26% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 1.05% 10-K · filed 2023-03-29 | |||
| 2021-09-30 | 0.94% 10-Q · filed 2022-11-10 | 1.04% 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | 0.86% 10-Q · filed 2022-08-10 | 1.04% 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | 1.06% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 1.03% 10-K · filed 2022-03-24 | |||
| 2020-09-30 | 1.06% 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | 0.47% 10-Q · filed 2021-08-11 | 1.06% 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |